Testosterone Cypionate Medicare Advantage Coverage: Costs, Formulary Status, and How to Get It Covered

Does Medicare Advantage Cover Testosterone Cypionate?

It can, but the member's plan documents control the answer. Medicare Advantage plans are offered by private insurers, and most (but not all) include Medicare drug coverage. Each plan with drug coverage maintains its own formulary, cost-sharing tiers, pharmacy network, and utilization-management rules [1][2].

Testosterone is not one of Medicare Part D's protected drug classes. A plan therefore is not required to cover every testosterone product. A plan may:

• list generic testosterone cypionate on a preferred or non-preferred tier;
• require prior authorization;
• apply a quantity limit;
• cover a different testosterone formulation;
• exclude a particular manufacturer, package size, or National Drug Code; or
• require a formulary exception.

Coverage can also change between plan years. Search the exact generic name, concentration, vial size, and National Drug Code in the current formulary rather than relying on a general statement about "TRT."

Part B Versus Part D

The benefit depends on who acquires and administers the drug.

Prescription Filled for Home Use

When a pharmacy dispenses testosterone cypionate for a patient to use at home, the claim is generally evaluated under Part D if the Medicare Advantage plan includes drug coverage. The product must satisfy the plan's formulary and coverage rules. The pharmacy can identify whether the claim was rejected because of:

• non-formulary status;
• prior authorization;
• a quantity limit;
• refill timing;
• an excluded National Drug Code; or
• a pharmacy-network restriction.

Provider-Supplied Office Injection

Medicare Part B covers a limited set of outpatient drugs and generally covers many injectable or infused drugs when a licensed medical provider supplies and administers them. A provider-supplied testosterone injection may therefore be evaluated under the medical benefit rather than the pharmacy benefit [3].

That is not a guarantee that every office-administered injection is payable. Medical necessity, diagnosis, coding, site of service, provider network, authorization, and the Medicare Advantage plan's cost sharing still matter. Ask the plan and clinic:

1. Will the clinic buy and bill the medication?
2. Is the drug covered under the Part B medical benefit for this diagnosis?
3. Does the service require prior authorization?
4. What are the drug and administration cost shares?
5. Is a specialty pharmacy required to supply the vial?

Comparing only the vial copay can be misleading because an office visit or administration charge may apply separately.

How to Check the Exact 2026 Coverage

Use the member's Evidence of Coverage, formulary, and authenticated price tool:

1. Confirm that the Medicare Advantage plan includes Part D coverage.
2. Search testosterone cypionate, not only a brand name.
3. Match the prescribed concentration and vial size.
4. Read any PA, ST, or QL codes.
5. Check the preferred pharmacy network.
6. Price the exact prescription at the intended pharmacy.
7. Separately ask about Part B coverage if the clinic will supply and administer it.

Medicare's Plan Compare tool can compare drugs and pharmacies across available plans, but the current plan and pharmacy should confirm the final amount before dispensing [4].

Prior Authorization and Diagnostic Documentation

Medicare permits drug plans to use prior authorization, step therapy, and quantity limits. Medicare also permits a member or prescriber to request an exception when a coverage rule is not medically appropriate [5].

There is no evidence-backed national rule that 60% of Medicare Advantage plans require testosterone-cypionate prior authorization. There is also no single Medicare-wide lab cutoff. Obtain the actual plan criteria.

Clinical sources do provide an evidence base for diagnosis:

• The current testosterone-cypionate label says to confirm hypogonadism with morning serum testosterone concentrations measured on at least two separate days and below the normal range [6].
• The American Urological Association guideline says clinicians should use a total testosterone level below 300 ng/dL as a reasonable cutoff and make the diagnosis only after two early-morning measurements, together with relevant symptoms or signs [7].
• The Endocrine Society guideline recommends diagnosing hypogonadism only when symptoms and signs are consistent with testosterone deficiency and testosterone concentrations are unequivocally and consistently low, confirmed with a repeat morning fasting measurement [8].

A plan can use its own coverage criteria, which may not mirror one guideline word-for-word. Commonly relevant records include the diagnosis, symptoms or signs, lab dates and reference ranges, causes being evaluated, requested product and dose, and reasons covered alternatives are inappropriate.

What Testosterone Cypionate Costs With Medicare Advantage

There is no reliable national $0-to-$30 copay. The amount can depend on:

• formulary tier;
• deductible status;
• copay versus coinsurance;
• preferred versus standard pharmacy;
• concentration, vial size, and National Drug Code;
• days' supply;
• Part B versus Part D billing; and
• Extra Help eligibility.

For 2026, Medicare says a Part D plan's deductible cannot exceed $615. The annual out-of-pocket limit for covered Part D drugs is $2,100, after which the member pays $0 for covered Part D drugs for the rest of the year [9]. A particular plan may have a lower deductible or use copays on some tiers.

Members receiving Extra Help pay no Part D deductible and no more than $5.10 for a generic or $12.65 for a brand-name covered prescription at a participating pharmacy in 2026, subject to the program's rules [10].

These are Medicare-wide benefit parameters, not a promise that testosterone cypionate is covered or that a particular fill will cost those amounts.

How to Respond to a Pharmacy Rejection

A pharmacy rejection is not always a final denial. Ask the pharmacy for the exact message and then contact the plan:

• Prior authorization required: Ask the prescriber to obtain the current criteria and submit the relevant clinical record.
• Quantity limit: Verify that the days' supply and vial size were entered correctly; request an exception if the prescribed quantity is medically necessary.
• Non-formulary: Ask whether another FDA-approved testosterone product is covered and whether a formulary exception is available.
• National Drug Code not covered: Ask whether a different covered manufacturer or package is available.
• Refill too soon: Confirm how the plan calculates days' supply for a single-dose or multidose vial.
• Wrong benefit: Ask whether a provider-administered product should be billed under the medical benefit.

Do not change a diagnosis or laboratory result to obtain payment. The submission must reflect the condition actually evaluated and treated.

Coverage Determinations and Appeals

A member or prescriber can ask the Part D plan for a coverage determination or exception before going to the pharmacy. A prescriber must provide a medical-support statement for an exception [11].

If the plan denies the request, follow the written notice. Medicare's current process includes five appeal levels. At Level 1, the plan generally has seven days for a standard benefit redetermination or 72 hours for a fast appeal. If the plan upholds the denial, the notice explains how to request Level 2 independent review, generally within 60 days [11].

Use an expedited request only when the plan or prescriber determines that waiting for a standard decision may seriously jeopardize the member's life, health, or ability to regain maximum function.

FDA Label and Current Safety Information

Current testosterone-cypionate injection labeling identifies the product as an intramuscular, Schedule III prescription drug used for replacement therapy in males with conditions associated with deficient or absent endogenous testosterone. The label requires confirmation with two separate morning measurements and says dosage and schedule must be individualized [6].

It is inaccurate to describe subcutaneous testosterone cypionate as the labeled route for a product whose label specifies intramuscular administration. A clinician may sometimes use a drug off label, but the article should not present that route as FDA-approved for every testosterone-cypionate product.

FDA's testosterone safety language has also changed:

• In February 2025, FDA removed boxed-warning language about increased adverse cardiovascular outcomes after reviewing TRAVERSE, while requiring warnings about increased blood pressure [12].
• FDA's current testosterone information page says the agency requested additional labeling updates in June 2026, including removal of the age-related-hypogonadism limitation and revisions to prostate and benign-prostatic-hyperplasia safety information [13].

Because exact product labels may be revised on different schedules, patients and clinicians should use the current label for the dispensed National Drug Code rather than an old class summary.

What TRAVERSE Does and Does Not Show

TRAVERSE enrolled 5,246 men with hypogonadism and preexisting or high cardiovascular risk. Testosterone gel was noninferior to placebo for major adverse cardiac events; the primary endpoint occurred in 7.0% of the testosterone group and 7.3% of the placebo group [14].

The trial informed FDA's class-wide cardiovascular labeling action. It did not compare office injections with home injections, prove that testosterone cypionate is risk-free, establish a Medicare coverage policy, or study every dosing regimen.

Testosterone treatment still requires individualized review and monitoring. Depending on the patient and guideline used, this can include response, serum testosterone, hematocrit, blood pressure, prostate-related evaluation, adverse effects, and fertility goals [7][8].

Compounded Testosterone and Medicare

Compounded testosterone should not be described as automatically uncovered by Part D or assigned a fixed $60-to-$120 price.

CMS says a compounded product may be coverable under Part D when it contains at least one ingredient that independently meets the Part D drug definition. Only qualifying Part D ingredients are allowable drug costs, and formulary or exception rules apply. A compound containing a Part B drug ingredient is handled under different rules [15].

Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing. An FDA-approved testosterone-cypionate product should generally be priced and checked for coverage before assuming a custom compound is necessary [16].

If a compound is proposed, ask:

• What patient-specific need cannot be met by an approved product?
• Which pharmacy will compound and dispense it?
• Is each ingredient covered, excluded, or cash-pay?
• What is the complete price including supplies and shipping?
• Is the pharmacy in the plan's network?

Practical Ways to Lower the Cost

• Check both Part D pharmacy coverage and Part B medical-benefit coverage.
• Use the exact National Drug Code and vial size when comparing prices.
• Ask whether a covered generic manufacturer is available.
• Compare preferred-network pharmacies.
• Verify how the plan calculates days' supply for the vial.
• Apply for Extra Help if eligible.
• Ask for a coverage determination before paying cash.
• If using a discount card instead of Medicare, ask whether the payment will count toward the Part D out-of-pocket limit; ordinarily it will not be a Part D claim.
• Compare total office costs, not only the drug price, when considering provider administration.